Loss-of-function mutations in PPP2R1A Correlate with Exceptional Survival in Ovarian Clear Cell Carcinomas Treated with Immune Checkpoint Inhibitors (099)Emily Hinchcliff, Amir A. Jazaeri, R. Tyler Hillman et al.|Gynecologic Oncology|2022Cited by 6
Abstract 1248: Predictors of innate resistance to pembrolizumab in patients with microsatellite instability-high endometrial cancerJeffrey How, Amir A. Jazaeri, Minghao Dang et al.|Cancer Research|2022Cited by 3
Intraperitoneal administration of dual immune checkpoint inhibitor therapy in recurrent gynecologic malignancies: Updated results of a phase 1b studyAnne Knisely, Amir A. Jazaeri, Emily Hinchcliff et al.|Gynecologic Oncology|2024Cited by 2
Phase Ib study of AVB-S6-500 (axl inhibition) in combination with durvalumab (MEDI4736) in patients with platinum-resistant, recurrent epithelial ovarian cancer (NCT04019288) (320)Emily Hinchcliff, Amir A. Jazaeri, Elisabeth Gardiner et al.|Gynecologic Oncology|2022Cited by 1
Abstract 5473: Genomic profiling of chemotherapy-related clonal hematopoiesis in patients with high-grade serous ovarian cancerSara Corvigno, Sanghoon Lee, Jun Yao et al.|Cancer Research|2023Cited by 1